{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NGF",
    "query": {
      "intervention": "NGF"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NGF&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T13:46:28.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06971939",
      "title": "Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Telangiectasia Type 2 (MacTel)"
      ],
      "interventions": [
        {
          "name": "NT-501/revakinagene taroretcel-lwey",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Neurotech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2025-11-21",
      "completion_date": "2032-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 23,
      "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06971939"
    },
    {
      "nct_id": "NCT01683539",
      "title": "Understanding How Cognitive Remediation Works",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Chronic Mental Disorder",
        "Major Depression",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "The Thinking Skills for Work Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "The Cognitive Skills for Work Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University Charles River Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2012-09",
      "completion_date": "2019-03-11",
      "has_results": false,
      "last_update_posted_date": "2019-03-13",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Manchester, New Hampshire",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Manchester",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01683539"
    },
    {
      "nct_id": "NCT00447980",
      "title": "A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "NT-501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurotech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 73,
      "start_date": "2007-01-22",
      "completion_date": "2010-04-19",
      "has_results": true,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00447980"
    },
    {
      "nct_id": "NCT03019627",
      "title": "An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "NGF",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-01-20",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2019-02-08",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03019627"
    },
    {
      "nct_id": "NCT05133180",
      "title": "Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Oxervate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2022-01-19",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 7,
      "location_summary": "Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05133180"
    },
    {
      "nct_id": "NCT04260087",
      "title": "New Daily Persistent Headache Biomarkers Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "New Daily Persistent Headache",
        "New Daily Persistent Headache (NDPH)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-05-01",
      "completion_date": "2021-11-18",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04260087"
    },
    {
      "nct_id": "NCT00095355",
      "title": "Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "Lithium",
          "type": "DRUG"
        },
        {
          "name": "Divalproex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "2004-10",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095355"
    },
    {
      "nct_id": "NCT00985621",
      "title": "Tanezumab In Osteoarthritis Of The Hip Or Knee",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "tanezumab 10 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tanezumab 5 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "oxycodone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 614,
      "start_date": "2009-10-30",
      "completion_date": "2011-02-04",
      "has_results": true,
      "last_update_posted_date": "2021-05-14",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985621"
    },
    {
      "nct_id": "NCT00505349",
      "title": "Blood Neurotrophic Factors in Adults",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Computer-based cognitive training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Posit Science Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2007-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2016-02-05",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505349"
    },
    {
      "nct_id": "NCT00715559",
      "title": "Cysteamine Therapy for Major Depressive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "cysteamine bitartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2008-07",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-02T13:46:28.984Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715559"
    }
  ]
}